Journal of Pathogens is a premier peer-reviewed journal published by HINDAWI LTD, focusing on the critical field of microbiology, infectious diseases, and the mechanisms of pathogen interactions with hosts. Since its inception in 2011 as an Open Access journal, it has aimed to provide a platform for high-quality research articles, reviews, and case studies that enhance our understanding of pathogenesis and advance the science of disease control. With its commitment to making research freely accessible, the journal attracts a global audience of researchers, professionals, and graduate students keen on exploring innovative findings and applications in the study of pathogens. While the journal does not currently have an established H-index or category quartiles, its relevance and importance in the field continue to grow as it seeks to bridge knowledge gaps and facilitate impactful discussions in infectious disease research. Located at Adam House, 3rd Floor, 1 Fitzroy Square, London W1T 5HF, England, the Journal of Pathogens invites submissions that contribute to the ever-evolving landscape of pathogen research and public health.

Annals of Clinical Microbiology and Antimicrobials, published by BMC, is a leading open-access journal that has been fostering scientific discourse in the fields of microbiology and infectious diseases since its inception in 2002. With an established reputation for excellence, this journal is positioned in the prestigious Q1 category across multiple disciplines, including Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology as of 2023. This journal serves as a vital platform for researchers, healthcare professionals, and students, promoting the latest advancements in clinical microbiology and antimicrobial research. Access to its invaluable content is open to all, reflecting the commitment to disseminate knowledge universally. The Annals of Clinical Microbiology and Antimicrobials is based in the United Kingdom and continues to pave the way for innovation and discussions that shape the future of clinical practices in microbiology.

Open Forum Infectious Diseases (ISSN: 2328-8957; E-ISSN: 2328-8957) is a leading open-access journal published by Oxford University Press, dedicated to advancing the field of infectious diseases. Since its inception in 2014, the journal has provided a platform for researchers to disseminate impactful findings in a rapidly evolving domain, achieving a remarkable Q1 ranking in both the Infectious Diseases and Oncology categories as of 2023. The journal encourages rigorous and innovative research, contributing significantly to global health discussions and informing best practices in clinical settings. As an open-access journal, it ensures that its content is accessible to a wide audience, fostering collaboration and knowledge sharing among researchers, professionals, and students alike. Positioned in the heart of the United States, Open Forum Infectious Diseases serves as a critical resource for the academic community, and its continued commitment to quality and relevance secures its status as an essential publication in the field.

New Microbiologica is a prominent academic journal published by EDIZIONI INT SRL, dedicated to advancing knowledge in the fields of Microbiology and Medicine. Since its inception in 1993, this journal has played a vital role in disseminating cutting-edge research, featuring articles that explore the intricate relationships between microorganisms and human health. With an H-index indicating a robust citation profile and a respectable 2023 Scopus Ranking placing it in the 32nd percentile for medicine microbiology, New Microbiologica resonates well within the academic community. Although not an Open Access journal, it is strategically positioned in Quartile 3 of both Medicine (miscellaneous) and Medical Microbiology categories, which reflects its importance to researchers and professionals seeking valuable insights in their fields. Published in Italy, the journal continues to provide a platform for impactful research through its commitment to high-quality publications, fostering collaboration and innovation among scientists and academics in the ever-evolving landscape of microbiological studies.

Infectious Diseases, published by TAYLOR & FRANCIS LTD, is a leading academic journal dedicated to advancing research in the field of infectious diseases and microbiology. With an impressive impact factor and categorized in Q1 in multiple areas including Immunology and Microbiology, this journal serves as a critical platform for researchers, practitioners, and students to disseminate their findings and stay abreast of current advancements. The journal is recognized for its rigorous peer-review process and aims to foster innovation and collaboration across disciplines from 2015 to 2024. It boasts a robust Scopus ranking, positioning it favorably among the top-tier of journals in the relevant fields, making it an essential resource for anyone involved in infectious disease research. Access options are available, ensuring that the latest research is accessible to a global audience, thus emphasizing the journal's commitment to promoting knowledge and understanding in the ever-evolving landscape of infectious diseases.

Mediterranean Journal of Infection Microbes and Antimicrobials is a distinguished open-access journal published by GALENOS PUBL HOUSE, dedicated to advancing the understanding of infectious diseases and microbiology. Since its inception in 2011, this journal has been a vital resource for researchers, professionals, and students interested in the intricate world of microbes and their impacts on human health. With its ISSN 2147-673X, the journal has progressively gained visibility, although it currently holds a Q4 ranking in multiple categories including Immunology and Microbiology, and Infectious Diseases for the year 2023. The journal operates from its headquarters in Istanbul, Turkey, and features a rich array of articles that contribute to the field’s body of knowledge. As a platform enhancing the accessibility of research, it invites submissions from global contributors to foster collaboration and innovation in tackling microbial challenges.

Microbial Drug Resistance, published by MARY ANN LIEBERT, INC, is a pivotal journal that explores the critical intersection of microbiology and pharmacology with a keen focus on antibiotic resistance and related issues. Since its inception in 1995, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for innovative studies that inform the global response to antimicrobial resistance. With a commendable position in the Category Quartiles, ranked Q2 in Medicine (miscellaneous) and Q2 in Pharmacology for 2023, it caters to a multidisciplinary audience by addressing the implications of microbial resistance within various medical contexts. Although currently non-Open Access, the journal allows subscribers and institutions to access high-quality, peer-reviewed research, directly impacting policy and practice in healthcare settings. Committed to advancing our understanding and combating the challenges posed by resistant microbes, Microbial Drug Resistance remains an essential publication in the fields of microbiology, immunology, and pharmacology.

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases is a leading peer-reviewed journal dedicated to advancing the field of infectious diseases, particularly focusing on tuberculosis and other mycobacterial infections. Published by ELSEVIER in the United Kingdom with an impressive open access model since 2015, this journal aims to provide a platform for the dissemination of high-quality research, clinical findings, and innovative methodologies in the management of mycobacterial diseases. With a commendable impact, the journal currently holds a Q2 ranking in multiple categories including Infectious Diseases and Pulmonary and Respiratory Medicine, reflecting its influence in the academic community. The journal is dedicated to serving researchers, healthcare professionals, and students by offering access to essential information that can improve patient outcomes and enhance public health strategies. As the field of mycobacterial diseases continues to evolve, Journal of Clinical Tuberculosis and Other Mycobacterial Diseases remains a crucial resource for those seeking to remain at the forefront of research and clinical practice.

JOURNAL OF CLINICAL MICROBIOLOGY, published by the American Society for Microbiology, stands as a premier resource for researchers and professionals in the field of medical microbiology. With an illustrious history dating back to 1975, this journal has consistently provided high-impact research, reflecting its status in the Q1 category among microbiology (medical) journals, and an impressive Scopus rank of 14 out of 140, placing it in the 90th percentile. The journal's commitment to unveiling foundational and innovative studies greatly contributes to understanding human health challenges posed by microbial pathogens. Researchers can expect rigorous peer-reviewed articles that cover a spectrum of topics, from diagnostic methods to clinical epidemiology, fostering a deeper understanding of microbiology's role in healthcare. While this journal does not offer open access options, its substantial impact factor underscores its relevance in shaping the conversation in clinical microbiology. The JOURNAL OF CLINICAL MICROBIOLOGY is indispensable for anyone dedicated to advancing their knowledge and practical skills in microbiology.

Infection and Chemotherapy, an esteemed journal published by the Korean Society of Antimicrobial Therapy, focuses on the dynamic fields of infectious diseases and pharmacology. With an ISSN of 2093-2340 and an E-ISSN of 2092-6448, this peer-reviewed, open-access journal has been providing a crucial platform for research dissemination since 2008. Based in South Korea, it boasts a significant impact in the academic community, as evidenced by its Q2 ranking in both Infectious Diseases and Pharmacology categories for 2023. It holds a Scopus rank of 64 out of 272 in Pharmacology and 98 out of 344 in Infectious Diseases, showcasing its prominence and the quality of research it publishes. With a focus on advancing scientific knowledge, Infection and Chemotherapy is committed to fostering essential dialogues among researchers, clinicians, and students, making it a vital resource for those engaged in the fight against infectious diseases and the development of effective therapeutic protocols.